Danish Medicines Agency to launch second reimbursement risk-sharing program
On Wednesday, pharmaceutical firms can apply to a trial scheme in Denmark where the public health system and private firms join forces to share the financial risks of expanding certain drug reimbursements.
by mikkel aabenhus hemmingsen, translated by daniel pedersen
The Danish Medicines Agency is ready for another risk-sharing scheme concerning reimbursements for prescription drugs. The original program, which spanned three years and ended in 2021, was aimed at opening reimbursement access for patients in Denmark.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Danish Medicines Council rejects Novartis breast cancer drug
For subscribers
Novo Nordisk regains Novorapid supply capacity
For subscribers
.jpg&w=384&q=75)
